Author name: Vincent Racaniello

I'm Professor of Microbiology and Immunology at Columbia University in New York. I run a research lab where we study poliovirus, rhinovirus, and other RNA viruses. I also love teaching about viruses - check out virology.ws, microbe.tv, or iTunes University for some of my offerings. I want to be Earth's virology professor.

Jake Scott put the ID in COVID-19

Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality. Hosts: Vincent Racaniello, Alan Dove, Rich Condit,  and Kathy Spindler Guest: Jake Scott Click arrow to playDownload TWiV 952 (63 MB .mp3, 104 …

Jake Scott put the ID in COVID-19 Read More »

TWiV 951: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective …

TWiV 951: Clinical update with Dr. Daniel Griffin Read More »

TWiV 950: Prion diseases with Richard Knight

From the European Society for Clinical Virology 2022 Conference in Manchester UK, Vincent speaks with Richard Knight about prion diseases and the outbreak of bovine spongiform encephalitis that led to cases of variant Creutzfeldt-Jakob disease in humans. Host: Vincent Racaniello Guest: Richard Knight Click arrow to playDownload TWiV 950 (68 MB .mp3, 114 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become …

TWiV 950: Prion diseases with Richard Knight Read More »

TWiV 949: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

TWiV 947: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials.

Scroll to Top